Yang CH, Chang CJ National Taiwan University Hospital, Taipei, Taiwan OBJECTIVE: Lung cancer is the leading cause of cancer death in Taiwan. According to the statistics published by the Taiwan Department of Health, 6555 patients died from lung cancer in 2001, and the mortality rate was 29.34 per 100,000 people. The purpose of this study was to analyze the direct cost of lung cancer management in Taiwan. METHODS: The claim database of the Bureau of National Health Insurance in Taiwan was used for this study, including the hospitalization and outpatient expenses for 2000 and 2001. The analyses comprised the average costs of hospitalization or outpatient services for lung cancer patients. RESULTS: Of the total hospitalization events for the year 2001, 56.86% were for chemotherapy administration (ICD-9-CM = V581). The average number of in-hospital days was 4.8, and the average cost for each event was NTD30, 648 (USD907.55) (1USD = 33.77NTD). Febrile neutropenia, thrombocytopenia, nausea and vomiting, neuropathy, and anemia were the common causes of hospitalization in large-scale global phase III clinical studies, but in Taiwan, only febrile neutropenia (144 events, NTD 47, 191 [USD 1, 397.42 
PCN19 THE COST-EFFECTIVENESS ANALYSIS RECOMBINANT HUMAN ERYTHROPOIETIN GROWTH FACTORS VS. TRANSFUSION IN CHEMOTHERAPY CANCER PATIENTS
Tonnu IQ, Hay JW USC School of Pharmacy, Los Angeles, CA, USA Chemotherapy-induced anemia is currently treated with recombinant human erythropoietin growth factors (rHu-EGFs) or transfusion. Currently, most studies find that that blood transfusion is more cost effective compared to rHu-EGFs due to the high cost and relatively small quality of life (QOL) improvements from the drugs. OBJECTIVES: To measure the cost effectiveness of using blood transfusion vs. rHu-EGFs in chemotherapytreated cancer patients from the societal perspective and cost per quality-adjusted life-year (QALY) approach. METHODS: A spreadsheet model was used to evaluate the cost effectiveness of erythropoietin (EPO) or darbepoietin (DARB) plus transfusion when needed, compared to transfusion only. The model applied clinical and QOL data from previous clinical trials and existing literature, in an expected present value backwards induction model using DEALE survival modeling to estimate cost per QALY. In the base case, patients were 60 years old, weighed 60 kg and used the manufacturer's recommended doses for chemotherapy-related anemia. The model's time horizon was one year. A sensitivity analysis was performed to determine model robustness. RESULTS: In the base case and relative to infusion only, for each patient who received EPO, the cost per QALY was $25,152, whereas, the cost per QALY was $45,646 for DARB. The sensitivity analysis suggested that the model was only sensitivity to QOL assumption, when the probability of infusion and anemia was altered by 25%, the cost per QALY values for EPO were $24,847-$25,473 and $21,419-$30,039, respectively. Also, an 81% reduction in DARB dose or price would be needed to equalize the cost of DARB treatment with that of EPO. CON-CLUSIONS: This economic model demonstrates that treating chemotherapy-related anemia using rHu-EGFs is more costeffective than transfusion only. Also, current clinical data suggests that there are no significant QALY differences between the rHu-EGFs. Thus, EPO would be the dominant alternative.
PCN20 PRELIMINARY ECONOMIC ANALYSIS OF THE AMERICAN CANCER SOCIETY GUIDELINES FOR MAMMOGRAPHY SCREENING IN AVERAGE-RISK WOMEN UNDER 70 YEARS OF AGE
Zammit D, Hay J University of Southern California, Los Angeles, CA, USA The American Cancer Society Guidelines (ACS) recommends women at average risk for breast cancer to begin annual
